Skip to content
DataLookout
Menu

IDUNNNCT07820813

bNAbs and Anti-PD-1 in HIV

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Sep 15, 2026 to Oct 7, 2026
    • Study sites: 0 to 1
    • Collaborators: 10 to 8
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Time from the day of stopping ART to the day of meeting criteria for loss of immunological control of HIV-1 (defined below)
Timeframe: 60 weeks

Secondary (7)

The safety and tolerability of the Investigational Medicinal Products (IMPs)
The frequency of post-interventional immunological control of HIV-1
The effect of the IMPs on HIV-1-specific T cells responses before, during and after the ATI
The effect of the IMPs on the intact HIV-1 reservoir before, during and after the ATI
The effect of the IMPs on the immune cell phenotype, activation and exhaustion
Show 2 moreShow less
The effect of autologous antibodies on post-interventional immunological control of HIV-1
bNAb sensitivity

Arms and interventions

A: bNAbs/anti-PD-1aExperimental

3BNC117-LS, 10-1074-LS and nivolumab

B: bNAbs/placeboActive comparator

3BNC117-LS, 10-1074-LS and placebo

Drugs: 3BNC117-LS, 10-1074-LS, Nivolumab

Other: Placebo

Sites

1 site in 1 country

  • Aarhus University HospitalAarhus, Denmark